New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Annals of Internal Medicine

• Publication date

  2006-12-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.7326/0003-4819-145-12-200612190-00008PMID 17179059
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

  2006influential reference
• A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL).

  2006cited by this paper
• Chronic myeloid leukemia in 2006 : a perspective

  2006cited by this paper
• Detection of BCR-ABL mutations and resistance to imatinib mesylate.

  2006cited by this paper
• Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005 'START-A' study.

  2006cited by this paper
• Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study.

  2006cited by this paper
• Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: Results of the CA180013 'START-C' Study.

  2006cited by this paper
• Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

  2006cited by this paper
• Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

  2006cited by this paper
• A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

  2005influential reference
• AMN107, a novel aminopyrimidine inhibitor of p190 Bcr‐Abl activation and of in vitro proliferation of Philadelphia‐positive acute lymphoblastic leukemia cells

  2005cited by this paper
• ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

  2005cited by this paper
• PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

  2005cited by this paper
• Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.

  2005cited by this paper
• AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia

  2005influential reference
• A small molecule–kinase interaction map for clinical kinase inhibitors

  2005cited by this paper
• Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

  2005influential reference
• Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

  2005cited by this paper
• Targeting BCR-ABL Kinase Activity-Independent Signaling Pathways and Leukemia Stem Cells Is Essential for Curative Therapy of Philadelphia Chromosome Positive (Ph+) Leukemia.

  2005cited by this paper
• Donor origin of multipotent adult progenitor cells in radiation chimeras.

  2005cited by this paper
• In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

  2005influential reference
• Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials.

  2004cited by this paper
• High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.

  2004cited by this paper
• P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

  2004cited by this paper
• Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

  2004cited by this paper
• Activity and Induction of Apoptosis of the Specific Tyrosine Kinase Inhibitor AMN 107 in bcr-abl + Cell Lines and in Imatinib Resistant Primary Cells from CML Patients.

  2004cited by this paper
• The Crystal Structure of Abl Kinase with BMS-354825, a Dual SRC/ABL Kinase Inhibitor.

  2004cited by this paper
• Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.

  2004cited by this paper
• Active transport of imatinib into and out of cells: implications for drug resistance.

  2004cited by this paper
• A Bcr/Abl-independent, Lyn-dependent Form of Imatinib Mesylate (STI-571) Resistance Is Associated with Altered Expression of Bcl-2*

  2004cited by this paper
• AMN107: In Vitro Profile of a New Inhibitor of the Tyrosine Kinase Activity of Bcr-Abl.

  2004cited by this paper
• Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

  2004cited by this paper
• Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells

  2004cited by this paper
• Practical management of patients with chronic myeloid leukemia receiving imatinib.

  2003cited by this paper
• BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

  2003cited by this paper
• Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C

  2003cited by this paper
• SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.

  2003cited by this paper
• Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate

  2003influential reference
• Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

  2003cited by this paper
• Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.

  2003cited by this paper
• Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.

  2003cited by this paper
• Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells.

  2003cited by this paper
• Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

  2003influential reference
• Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

  2003cited by this paper
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

  2003cited by this paper
• A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.

  2003cited by this paper
• SRC family kinases: potential targets for the treatment of human cancer and leukemia.

  2003cited by this paper
• Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia.

  2003cited by this paper
• Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

  2002cited by this paper
• High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.

  2002cited by this paper
• Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

  2002cited by this paper
• BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.

  2002cited by this paper
• Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

  2002cited by this paper
• Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

  2002cited by this paper
• Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr–Abl signal transduction and oncogenesis

  2002cited by this paper
• Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.

  2002cited by this paper
• Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).

  2002cited by this paper
• Reduced focal adhesion kinase and paxillin phosphorylation in BCR‐ABL‐transfected cells

  2002cited by this paper
• Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.

  2002cited by this paper
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  2002cited by this paper
• Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

  2002cited by this paper
• Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.

  2002cited by this paper
• A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.

  2002cited by this paper
• Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

  2002cited by this paper
• Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

  2001cited by this paper
• BCR-ABL down-regulates the DNA repair protein DNA-PKcs.

  2001cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance.

  2001cited by this paper
• The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells.

  2000cited by this paper
• Transformation of Myeloid Leukemia Cells to Cytokine Independence by Bcr-Abl Is Suppressed by Kinase-defective Hck*

  2000cited by this paper
• Role of 1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL + Leukemic Cells to the Abl Inhibitor STI 571

  2000cited by this paper
• Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

  2000cited by this paper
• Outcome of Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia

  2000cited by this paper
• Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

  1999cited by this paper
• An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.

  1999cited by this paper
• Chronic myelogenous leukemia in nonlymphoid blastic phase

  1999cited by this paper
• Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth

  1999cited by this paper
• Chronic Myelogenous Leukemia: Biology and Therapy

  1999cited by this paper
• Chronic myeloid leukemia.

  1999cited by this paper
• The tetramerization domain-independent Ras activation by BCR-ABL oncoprotein in hematopoietic cells.

  1998cited by this paper
• Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.

  1997cited by this paper
• Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.

  1997cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996cited by this paper
• Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.

  1996cited by this paper
• P210 and P190BCR/ABL Induce the Tyrosine Phosphorylation and DNA Binding Activity of Multiple Specific STAT Family Members*

  1996cited by this paper
• Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.

  1995cited by this paper
• Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service.

  1995cited by this paper
• Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.

  1995cited by this paper
• BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.

  1995cited by this paper
• Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon- Therapy

  1995cited by this paper
• Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated with recombinant interferon alpha.

  1994cited by this paper
• Chronic myelogenous leukemia: biology and therapy.

  1993cited by this paper
• Intensive chemotherapy induction followed by interferon‐alpha maintenance in patients with Philadelphia chromosome‐positive chronic myelogenous leukemia

  1991cited by this paper
• Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

  1990cited by this paper
• Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

  1990cited by this paper
• Acute leukaemia in bcr/abl transgenic mice

  1990cited by this paper
• A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining

  1973cited by this paper
• Chromosome studies on normal and leukemic human leukocytes.

  1960cited by this paper

• Bridging the Gap Between Static Histology and Dynamic Organ-on-a-Chip Models.

  2026cites this paper
• Key Determinants of the Chemo-Sensitizing Activity of Novel Telmisartan Derivatives

  2025cites this paper
• Circumventing Imatinib resistance in CML: Novel Telmisartan-based cell death modulators with improved activity and stability.

  2024cites this paper
• New Derivatives of 1-(3-Methyl-1-Benzofuran-2-yl)Ethan-1-one: Synthesis and Preliminary Studies of Biological Activity

  2024cites this paper
• Evolution of therapeutic approaches in patients with chronic myeloid leukemia and T315I mutation

  2024cites this paper
• Critical role of protein kinase CK2 in chronic myeloid leukemia cells harboring the T315I BCR::ABL1 mutation.

  2024cites this paper
• Methyl-Thiol-Bridged Oxadiazole and Triazole Heterocycles as Inhibitors of NF-κB in Chronic Myelogenous Leukemia Cells

  2023cites this paper
• Effects of

  2023cites this paper
• Brassinin Induces Apoptosis, Autophagy, and Paraptosis via MAPK Signaling Pathway Activation in Chronic Myelogenous Leukemia Cells

  2023cites this paper
• Recent Insights and Promising Applications of Plant Disease Resistance Genes: A Review

  2022cites this paper
• Piperlongumine overcomes imatinib resistance by inducing proteasome inhibition in chronic myelogenous leukemia cells.

  2022cites this paper
• Association between Perceived Stress and Neutropenia in Patients with Leukemia under Chemotherapy

  2022cites this paper
• Leelamine Modulates STAT5 Pathway Causing Both Autophagy and Apoptosis in Chronic Myelogenous Leukemia Cells

  2022cites this paper
• Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia

  2022cites this paper
• Antileukemic Activity of hsa-miR-203a-5p by Limiting Glutathione Metabolism in Imatinib-Resistant K562 Cells

  2022cites this paper
• Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness

  2021cites this paper
• vHTS, 3-D Pharmacophore, QSAR and Molecular docking Studies for the Identification of Phyto-derived ATP-Competitive Inhibitors of the BCR-ABL Kinase Domain.

  2021cites this paper
• Polymeric siRNA delivery targeting integrin-β1 could reduce interactions of leukemic cells with bone marrow microenvironment

  2021cites this paper
• Icaritin induces cellular senescence by accumulating the ROS production and regulation of the Jak2/Stat3/p21 pathway in imatinib-resistant, chronic myeloid leukemia cells.

  2021cites this paper
• Effect of D-mannose on Philadelphia chromosome-positive leukemia cells

  2021cites this paper
• Pyrimethamine Modulates Interplay between Apoptosis and Autophagy in Chronic Myelogenous Leukemia Cells

  2021cites this paper
• Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia with e1a3 BCR-ABL1 transcript in a Nigerian with sickle cell anemia: a case report

  2021influential citation
• LncRNA highly upregulated in liver cancer regulates imatinib resistance in chronic myeloid leukemia via the miR-150-5p/MCL1 axis

  2021cites this paper
• The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies.

  2021cites this paper
• Synthesis and Characterization of Telmisartan‐Derived Cell Death Modulators to Circumvent Imatinib Resistance in Chronic Myeloid Leukemia

  2020cites this paper
• Nilotinib treatment of patients affected by chronic graft-versus-host disease reduces collagen production and skin fibrosis by down-modulating the TGF-β and p-SMAD pathway.

  2020cites this paper
• Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells

  2020cites this paper
• Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer

  2020cites this paper
• In Silico Study of Potential Cross-Kingdom Plant MicroRNA Based Regulation in Chronic Myeloid Leukemia

  2020cites this paper
• Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population

  2020cites this paper
• BCR-ABL Gene Transcript Types of Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia

  2020cites this paper
• Myeloproliferative neoplasms

  2020cites this paper
• A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway

  2020cites this paper
• Allosteric inhibitors of the STAT3 signaling pathway.

  2020cites this paper
• Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells.

  2020cites this paper
• AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitor‑sensitive and ‑resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora B.

  2020cites this paper
• Comparison of RT-qPCR and RT-Digital PCR for Detection and Quantification of BCR-ABL1 Transcripts in Chronic Myeloid Leukemia

  2019cites this paper
• Imatinib Induced Delayed and Refractory Generalized Fluid Retention: A Case Report and Review of Literature

  2019influential citation
• miR-302 cluster inhibits angiogenesis and growth of K562 leukemia cells by targeting VEGFA

  2019cites this paper
• USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia

  2019cites this paper
• Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients

  2018cites this paper
• Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system

  2018cites this paper
• Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells.

  2018cites this paper
• A Chemical Approach to Overcome Tyrosine Kinase Inhibitors Resistance : Learning from Chronic Myeloid Leukemia.

  2018cites this paper
• Indole-3-carbinol induces apoptosis of chronic myelogenous leukemia cells through suppression of STAT5 and Akt signaling pathways

  2017cites this paper
• Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation

  2017cites this paper
• Myeloid Leukemia – Clinical Diagnosis and Treatment 96 2 . Molecular mechanisms of BCR-ABL

  2017cites this paper
• On-Chip Peptide Mass Spectrometry Imaging for Protein Kinase Inhibitor Screening.

  2017cites this paper
• Chromosomes and Chromosomal Instability in Human Cancer

  2017cites this paper
• Clinical features and outcomes in chronic myeloid leukemia with T 315 I mutation

  2017cites this paper
• Induction of p53 suppresses chronic myeloid leukemia

  2017cites this paper
• Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy

  2017cites this paper
• Biochemical and chemical characterization of Cynara cardunculus L. extract and its potential use as co-adjuvant therapy of chronic myeloid leukemia.

  2017cites this paper
• Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms

  2016cites this paper
• A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia

  2016cites this paper
• Pharmacokinetics and excretion of 14C-omacetaxine in patients with advanced solid tumors

  2016cites this paper
• Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients

  2016cites this paper
• Tyrosine Kinase Inhibitors in Ph+ Chronic Myeloid Leukemia Therapy: a Review.

  2016cites this paper
• Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance

  2016cites this paper
• miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes

  2016cites this paper
• ABCG 2 C 421 A Polymorphism and Imatinib Response in Chronic Myeloid Leukemia : A Systematic Review and Meta-Analysis

  2016cites this paper
• Effect of STAT3 inhibitor in chronic myeloid leukemia associated signaling pathway: a mathematical modeling, simulation and systems biology study

  2016cites this paper
• Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib

  2016cites this paper
• Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia

  2016cites this paper
• Significance of neuropilin-1 mRNA expression in chronic myeloid leukemia

  2016cites this paper
• In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study

  2016cites this paper
• Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes

  2016cites this paper
• Metabolite profiling of 14C-omacetaxine mepesuccinate in plasma and excreta of cancer patients

  2016cites this paper
• Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells

  2016cites this paper
• CHRONIC MYELOGENOUS LEUKEMIA: A REVIEW AND UPDATE OF CURRENT AND FUTURE THERAPY

  2016cites this paper
• Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation

  2016cites this paper
• Imatinib for treating patients with chronic myelogeneous leukemia

  2015cites this paper
• Eradication of T315I mutation in chronic myeloid leukemia without third-generation tyrosine kinase inhibitor: a case report.

  2015cites this paper
• Evaluación económica del dasatinib en el tratamiento de la leucemia mieloide crónica en pacientes resistentes al imatinib en Perú, versus nilotinib y dosis mayores de imatinib

  2015cites this paper
• Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up

  2015cites this paper
• Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation

  2015cites this paper
• Gambogic acid induces death of K562 cells through autophagy and apoptosis mechanisms

  2015cites this paper
• Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor

  2015cites this paper
• Micrornas as therapeutic targets

  2015cites this paper
• Inhibitor Mediated Bcr-Abl Degradation: A Novel Therapeutic Approach for Chronic Myeloid Leukemia

  2015cites this paper
• Bifurcation patterns in generalized models for the dynamics of normal and leukemic stem cells with signaling

  2015cites this paper
• A novel compound against oncogenic Aurora kinase A overcomes imatinib resistance in chronic myeloid leukemia cells.

  2015cites this paper
• Identification of Dual Natural Inhibitors for Chronic Myeloid Leukemia by Virtual Screening, Molecular Dynamics Simulation and ADMET Analysis

  2015cites this paper
• Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia

  2014cites this paper
• Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells

  2014cites this paper
• LEUCEMIA MIELÓIDE CRÓNICA: DESAFIOS NO TRATAMENTO DA FASE BLÁSTICA. A propósito de um caso clínico

  2014cites this paper
• BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.

  2014cites this paper
• BCR‐ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein

  2014cites this paper
• Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation

  2014cites this paper
• ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate

  2014cites this paper
• Heterogeneity of BCR-ABL rearrangement in patients with chronic myeloid leukemia in Pakistan

  2014cites this paper
• Bosutinib treatment for Philadelphia chromosome-positive leukemias.

  2014cites this paper
• MicroRNA-520a-5p displays a therapeutic effect upon chronic myelogenous leukemia cells by targeting STAT3 and enhances the anticarcinogenic role of capsaicin

  2014cites this paper
• 2-tert-butyl-1,4-benzoquinone Induces Apoptosis in Chronic Myeloid Leukemia Cells Resistant to Imatinib via Inducing Caspase-Dependent Bcr-

  2014cites this paper
• Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia

  2014cites this paper
• Multidrug resistance in chronic myeloid leukemia

  2014cites this paper
• A SMO inhibitor drug reduces the progenitor cell's maintenance in the Drosophila hematopoietic organ: a novel model to study Chronic Myelogenous Leukemia relapse

  2014cites this paper
• A Comparative Effectiveness Analysis of Patients Newly Initiating Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia

  2014cites this paper
• 2-tert-butyl-1,4-benzoquinone Induces Apoptosis in Chronic MyeloidLeukemia Cells Resistant to Imatinib via Inducing Caspase-Dependent Bcr-Abl Downregulation

  2014cites this paper
• Inhibition of autophagy augments the anticancer activity of α-mangostin in chronic myeloid leukemia cells

  2014cites this paper